MA32167B1 - Dérivés d'imidazo[1,2-b]pyridazine pour le traitement de maladies médiées par la tyrosine kinase c-met - Google Patents

Dérivés d'imidazo[1,2-b]pyridazine pour le traitement de maladies médiées par la tyrosine kinase c-met

Info

Publication number
MA32167B1
MA32167B1 MA33198A MA33198A MA32167B1 MA 32167 B1 MA32167 B1 MA 32167B1 MA 33198 A MA33198 A MA 33198A MA 33198 A MA33198 A MA 33198A MA 32167 B1 MA32167 B1 MA 32167B1
Authority
MA
Morocco
Prior art keywords
treatment
tyrosine kinase
imidazo
mediated diseases
kinase mediated
Prior art date
Application number
MA33198A
Other languages
Arabic (ar)
English (en)
Inventor
Pascal Furet
Clive Mccarthy
Joseph Schoepfer
Carsten Spanka
Melanie Stang
Frédéric Stauffer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39672115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32167(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32167B1 publication Critical patent/MA32167B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule (i) et des sels de ceux-ci, formule (i), dans lesquels les substituants sont comme défini dans la spécification, l'application d'un composé de formule (i) dans un procédé pour le traitement du corps humain ou animal, en particulier en ce qui concerne une maladie médiée par la tyrosine kinase c-met; l'utilisation d'un composé de formule (i) pour fabriquer un médicament pour le traitement de telles maladies; des compositions pharmaceutiques comprenant un composé de formule (i), facultativement en présence d'un partenaire de combinaison; des procédés pour la préparation d'un composé de formule (i).
MA33198A 2008-02-28 2010-09-24 Dérivés d'imidazo[1,2-b]pyridazine pour le traitement de maladies médiées par la tyrosine kinase c-met MA32167B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08152068 2008-02-28
PCT/EP2009/052302 WO2009106577A1 (fr) 2008-02-28 2009-02-26 Dérivés d’imidazo[1,2-b]pyridazine pour le traitement de maladies médiées par la tyrosine kinase c-met

Publications (1)

Publication Number Publication Date
MA32167B1 true MA32167B1 (fr) 2011-03-01

Family

ID=39672115

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33198A MA32167B1 (fr) 2008-02-28 2010-09-24 Dérivés d'imidazo[1,2-b]pyridazine pour le traitement de maladies médiées par la tyrosine kinase c-met

Country Status (25)

Country Link
US (1) US8822468B2 (fr)
EP (1) EP2265614A1 (fr)
JP (1) JP5576802B2 (fr)
KR (1) KR20100128305A (fr)
CN (1) CN102015716B (fr)
AR (1) AR070487A1 (fr)
AU (1) AU2009218459A1 (fr)
BR (1) BRPI0908504A2 (fr)
CA (1) CA2717034A1 (fr)
CL (1) CL2009000443A1 (fr)
CO (1) CO6300957A2 (fr)
CR (1) CR11620A (fr)
DO (1) DOP2010000263A (fr)
EA (1) EA201001365A1 (fr)
EC (1) ECSP10010427A (fr)
IL (1) IL207434A0 (fr)
MA (1) MA32167B1 (fr)
MX (1) MX2010009414A (fr)
NI (1) NI201000145A (fr)
PE (1) PE20091468A1 (fr)
SM (1) SMAP201000112A (fr)
TW (1) TW200940545A (fr)
UY (1) UY31676A1 (fr)
WO (1) WO2009106577A1 (fr)
ZA (1) ZA201005602B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
US20110053968A1 (en) 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
US8389526B2 (en) * 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (fr) 2009-08-12 2012-06-20 Novartis AG Composés hydrazone hétérocycliques et leurs utilisations pour traiter le cancer et l'inflammation
CA2771432A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composes d'oximes heterocycliques
PL2719699T3 (pl) 2009-12-31 2016-01-29 Hutchison Medipharma Ltd Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania
US20110195066A1 (en) * 2010-02-05 2011-08-11 Auspex Pharmaceuticals, Inc. Quinoline inhibitors of tyrosine kinase
WO2012003338A1 (fr) * 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited Combinaison d'un inhibiteur de cmet et d'un anticorps dirigé contre hgf et/ou cmet
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2723748B1 (fr) * 2011-06-22 2016-10-12 Bayer Intellectual Property GmbH Hétérocyclylaminoimidazopyridazines
CN103958509B (zh) * 2011-09-15 2015-12-23 诺华股份有限公司 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
PT2925757T (pt) 2012-11-19 2018-01-09 Novartis Ag Compostos e composições para o tratamento de doenças parasitárias
CN105431148A (zh) 2013-03-07 2016-03-23 加利菲亚生物公司 混合谱系激酶抑制剂及治疗方法
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
CN105326793A (zh) * 2014-08-06 2016-02-17 中美冠科生物技术（太仓）有限公司 一种包含c-Met激酶抑制剂的固体分散体及其制备方法和用途
ES2760507T3 (es) * 2014-12-19 2020-05-14 Janssen Pharmaceutica Nv Derivados de imidazopiridazina enlazados a heterociclilo como inhibidores de PI3Kß
DK3233862T3 (da) * 2014-12-19 2019-10-07 Janssen Pharmaceutica Nv Imidazopyridazinderivater som pi3k-beta-inhibitorer
CA3032210A1 (fr) * 2016-09-16 2018-03-22 Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Inhibiteurs de traf 6
WO2018138050A1 (fr) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Dérivés hétérocycliques bicycliques condensés utilisés comme pesticides
WO2018237349A1 (fr) * 2017-06-23 2018-12-27 University Of Washington Inhibiteurs de méthionyl-arnt synthétase de type 1 et leurs méthodes d'utilisation
JP2023506951A (ja) * 2019-12-18 2023-02-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｌｉｎ２８の阻害剤及びその使用方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489755A (en) * 1966-08-03 1970-01-13 Pfizer & Co C Imidazo (1,2-b) pyridazines
GB8719368D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Heterocyclic compounds
FR2619818B1 (fr) * 1987-09-01 1990-01-12 Sanofi Sa Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2057089A1 (fr) 1990-12-07 1992-06-08 Eric E. Allen Derives de substitution de pyrazolopyrimidines and d'imidazopyridazines, antagonistes de l'angiotensine ii
AU2001252609A1 (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd. Imidazopyridine derivatives
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
AU2003297160A1 (en) 2002-12-18 2004-07-22 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
JP2007521297A (ja) 2003-06-30 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体モジュレータとしての１７−アセトアミド−４−アザステロイド誘導体
US7037909B2 (en) 2003-07-02 2006-05-02 Sugen, Inc. Tetracyclic compounds as c-Met inhibitors
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
AU2004285452A1 (en) 2003-10-21 2005-05-12 Merck & Co., Inc. Triazolo-pyridazine compounds and derivatives thereof useful in the treatment of neuropathic pain
WO2005051302A2 (fr) 2003-11-19 2005-06-09 Array Biopharma Inc. Inhibiteurs bicycliques de mek, et leurs procedes d'utilisation
JP2007518823A (ja) 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
CA2555263A1 (fr) 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines et ligands associes des recepteurs de benzodiazepine
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
KR100973609B1 (ko) * 2005-03-23 2010-08-03 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ2 길항제로서 아세틸렌일-피라졸로-피리미딘유도체
WO2006124354A2 (fr) 2005-05-12 2006-11-23 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
WO2007013673A1 (fr) * 2005-07-29 2007-02-01 Astellas Pharma Inc. Hétérocycles fusionnés en tant qu’inhibiteurs de lck
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7348325B2 (en) * 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
AU2006320580B2 (en) 2005-11-30 2011-06-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
ME02736B (fr) 2005-12-21 2017-10-20 Janssen Pharmaceutica Nv Triazolopyridazines en tant que modulateurs de la tyrosine kinase
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
JP2009538899A (ja) 2006-05-30 2009-11-12 ファイザー・プロダクツ・インク トリアゾロピリダジン誘導体
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) * 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
WO2008016192A2 (fr) 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Dérivé hétérocyclique fusionné et son procédé d'utilisation
CA2660836A1 (fr) * 2006-08-07 2008-02-21 Incyte Corporation Utilisation de triazolotriazines en tant qu'inhibiteurs des kinases
US20100144738A1 (en) 2006-09-05 2010-06-10 William Bornmann Inhibitors of c-met and uses thereof
WO2008030579A2 (fr) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulateurs de la kinase associée au récepteur de l'interleukine-1
ES2393132T3 (es) 2006-10-23 2012-12-18 Sgx Pharmaceuticals, Inc. Moduoladores de proteína quinasa de triazolopiridazina
EA026126B1 (ru) 2006-11-22 2017-03-31 Инсайт Холдингс Корпорейшн Имидазотриазины и имидазопиримидины в качестве ингибиторов киназы
AR064420A1 (es) * 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
US8125627B2 (en) 2007-04-27 2012-02-28 Alakai Defense Systems, Inc. Laser spectroscopy system
WO2008155378A1 (fr) 2007-06-21 2008-12-24 Janssen Pharmaceutica Nv Formes polymorphes et hydratées, sels et procédé de préparation de la 6-{difluoro[6-(1-méthyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]méthyl}quinoléine
WO2009060197A1 (fr) * 2007-11-08 2009-05-14 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyridazines utilisées comme qu'inhibiteurs de protéine kinases
WO2009088955A2 (fr) 2007-12-31 2009-07-16 Energenox, Inc. Turbine à effet de couche limite
JP2009227599A (ja) 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体

Also Published As

Publication number Publication date
CN102015716B (zh) 2014-09-17
US20090264406A1 (en) 2009-10-22
CN102015716A (zh) 2011-04-13
JP5576802B2 (ja) 2014-08-20
DOP2010000263A (es) 2010-09-30
IL207434A0 (en) 2010-12-30
CR11620A (es) 2010-10-08
UY31676A1 (es) 2009-09-30
NI201000145A (es) 2011-03-02
CL2009000443A1 (es) 2010-09-10
ZA201005602B (en) 2011-04-28
BRPI0908504A2 (pt) 2015-08-11
EA201001365A1 (ru) 2011-04-29
CA2717034A1 (fr) 2009-09-03
CO6300957A2 (es) 2011-07-21
TW200940545A (en) 2009-10-01
MX2010009414A (es) 2010-09-24
PE20091468A1 (es) 2009-10-22
AU2009218459A1 (en) 2009-09-03
ECSP10010427A (es) 2010-09-30
US8822468B2 (en) 2014-09-02
SMAP201000112A (it) 2010-11-12
EP2265614A1 (fr) 2010-12-29
WO2009106577A1 (fr) 2009-09-03
AR070487A1 (es) 2010-04-07
KR20100128305A (ko) 2010-12-07
JP2011513279A (ja) 2011-04-28

Similar Documents

Publication Publication Date Title
MA32167B1 (fr) Dérivés d'imidazo[1,2-b]pyridazine pour le traitement de maladies médiées par la tyrosine kinase c-met
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
NO20063758L (no) Pyrazolo[1,5-A]pyrimidin-7-yl-amin derivater for anvendelse i behandling av proteinkinase avhengige sykdommer
ATE329596T1 (de) Phthalazinderivate zur behandlung von entzündlicher erkrankungen
WO2010066684A3 (fr) Inhibiteurs pyridyloxyindoles de vegf-r2 et utilisation thérapeutique de ceux-ci
EA200900388A1 (ru) Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus
BRPI0509069A (pt) compostos de imidazol para o tratamento de distúrbios neurodegenerativos
MY187131A (en) Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
EA200870373A1 (ru) Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ
TW200613305A (en) Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
EP1973407A4 (fr) Composes spiro et procedes d utilisation
CL2008003056A1 (es) Compuestos derivados de 3-fenil-imidazo[1,2-a]piridinas; composicion farmaceutica; proceso para su preparacion, util como inhibidores de alk-5 o alk-4 en el tratamiento de enfermedades inflamatorias u obstructivas de las vias respiratorias, cancer, enfermedades musculares, trastornos esqueleticos
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
EA201101704A1 (ru) ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА
ATE316077T1 (de) Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
BRPI0513750A (pt) 2-fenilamino-benzamidas-5-substituìdas como inibidoras de mek
UA103617C2 (ru) Производные тиенопиридона как активаторы амр-активированной протеинкиназы (амрк)
WO2009007748A3 (fr) Composés 945
WO2008065068A3 (fr) Dihydroimidazoles substitués et leur utilisation dans le traitement de tumeurs
EA200700637A1 (ru) Соли донепезила, подходящие для получения фармацевтических композиций
BRPI0509468A (pt) 1,3,4-oxadiazol-2-onas como modulares de ppar delta e usos das mesmas
BRPI0715609A2 (pt) Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
HRP20050739A2 (en) Cycloalkyl-substituted alkanoic acid derivatives, methods for the production thereof, and use thereof as a medicament
TN2010000390A1 (en) Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
EA200600318A1 (ru) ПРОИЗВОДНЫЕ 3-НИТРОПИРАЗОЛО[1,5-a]ПИРИМИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО (ВАРИАНТЫ) И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРА ГАМК(ВАРИАНТЫ)